For patients with brain metastases, amino acid PET can provide valuable information about the effectiveness of state-of-the-art treatments. When treatment monitoring with contrast-enhanced MRI is unclear, adding 18F-FET PET can help to accurately diagnose recurring brain metastases and reliably assess patient response. This research was published in The Journal of Nuclear Medicine.
Newer treatment options for patients with brain metastases—such as immune checkpoint inhibitors and targeted therapies—are effective, but can cause a variety of side effects. As a result, imaging findings on contrast-enhanced MRI can be highly variable, and it can be difficult to tell whether a treatment is working.
“Essentially, these new treatments have requirements of brain imaging which cannot be met by conventional MRI,” says Norbert Galldiks, MD, professor of neurology, neurologist, and neuro-oncologist at the University Hospital Cologne and Research Center in Juelich, Germany. “In our study, we tried to determine if adding 18F-FET PET could help to overcome some of these imaging challenges.”
The retrospective study included melanoma and lung cancer patients with brain metastases who had been treated with immune checkpoint inhibitors or targeted therapy alone or in combination with radiotherapy. 18F-FET PET imaging was shown to be a useful method when conventional MRI was inconclusive. It could correctly diagnose brain metastasis relapses and identify patients who were responding to treatment and those who were not.
“In cases of ambiguous MRI findings, supplemental FET PET is helpful for treatment monitoring. It provides physicians with a longer time window for subsequent patient management and allows them to optimize the treatment strategy for each individual patient,” notes Galldiks. “Since this approach is so accurate, it has the potential to influence clinical decision making. This may help to reduce the number of invasive procedures and limit overtreatment for a considerable number of seriously ill patients with brain metastases.”
Featured image: After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), 18F-FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, −28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 months. CE=contrast-enhanced.